KYG6096M1226 - Common Stock
APTORUM GROUP LTD-CLASS A
NASDAQ:APM (4/25/2024, 12:10:03 PM)
5.55
-0.01 (-0.18%)
Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. The firm is focused on the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The firm's business segments include Therapeutics and Non-Therapeutics. Therapeutics segment is engaged in developing various drug molecules and certain technologies for treatment of human disease conditions. Two of the Company’s lead projects, ALS-4 and SACT-1, target infectious disease and cancer, including orphan oncology indications. Non-Therapeutics segment encompasses three businesses: diagnostics projects including PathsDx Test, natural supplements including NativusWell, and AML Clinic. PathsDx Test is a novel molecular-based rapid pathogen identification and detection diagnostics technology, which is under co-development with A*STAR.
APTORUM GROUP LTD-CLASS A
17 Hanover Square
London W1S 1BN
P: 442080929299
CEO: Ian Huen
Employees: 18
Website: http://www.aptorumgroup.com/
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
We’re using the Portfolio Grader to find the best biotech stocks to buy in today’s market. Each of these stocks get top grades.
What's going on in today's session
Pre-market stock movers are worth checking out on Thursday to get an idea of the hottest stocks worth watching this morning!
Aptorum has announced a reverse merger deal with AI specialist YOOV Group. Now, APM stock is soaring thanks to sector-related sentiment.
Here you can normally see the latest stock twits on APM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: